Impact in the Medical Care Among the Rheumatic Diseases Patients in a Hospital in México During COVID-19 Pandemic

National Institute of Medical Sciences and Nutrition, Salvador Zubiran

Status: Completed

Conditions: Quality of Life; Rheumatoid Arthritis

Treatments: Other: DASS-21 instrument (depression and anxiety); Other: COVID-19 survey; Other: WHOQOL-BREF; Other: IER-R (posttraumatic stress); Other: RAPID-3

Study type: Observational

Funder types: Other

Identifiers

NCT04557358

IRE-3467

Details and patient eligibility

About

The National Institute of Medical Sciences and Nutrition is a national reference center for rheumatic diseases that belongs to The National Institutes of Health, and has Federal founding. More than 8,000 patients with a wide variety of rheumatologic diagnosis receive medical care.

On March 2020, the WHO announced COVID-19 outbreak a pandemic. The first case was registered in Mexico on February 2020. In March 2020, the Mexican Government requested that our Institution should restrict health care to exclusively COVID-19 patients; accordingly, outpatient consultations were, and up to August 2020 still, hold on.

Meanwhile, when possible, the Department of Immunology and Rheumatology has implemented an "on-demand", non-organized patient´s health care, through email and phone contact; nonetheless, and due to the middle-low socioeconomic status of most of our patients and limited technical resources available at our Institution, the attempt has been challenging.

Full description

The aim objective of this project is to explore patients perception about access to medical care and to medications, access to communication with their primary rheumatologist and patients risk perception about COVID-19 disease, for this a survey directed (questionnaire locally developed) will apply and to explore how the reintegration at the usual medical care has a positive impact in the patient´s disease activity, patient´s quality of life and psychopathology (depression, anxiety and posttraumatic stress).

Enrollment: 670 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a rheumatic disease diagnosis according to their primary rheumatologist who agree to participate

Exclusion criteria

• Patients with a not confirmed rheumatic disease
• Patients lost to follow-up from the outpatient for > 1 year period
• Patients with pregnancy plans

Trial design

670 participants in 1 patient group

Rheumatic diseases outpatients

Description:

All the rheumatic diseases outpatients from the National Institute of Medical Sciences and Nutrition that will assist their usual medical care posterior of stopped it during the COVID-19 pandemic. In order to explore how the patient´s disease activity, patient´s quality of life, and psychopathology will change with the reintegration at medical care, randomization 200 rheumatic diseases outpatients that will respond RAPID-3 (disease activity/disease severity), WHOQOL-BREF instrument (quality of life), DASS-21 instrument (depression and anxiety), IER-R (posttraumatic stress)

Treatment:

Other: IER-R (posttraumatic stress)

Other: RAPID-3

Other: COVID-19 survey

Other: DASS-21 instrument (depression and anxiety)

Other: WHOQOL-BREF